open access
Osilodrostat — an emerging drug for the medical management of Cushing’s disease
, 1, 1, 2, 2
Affiliations- Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of Warsaw, Poland
- Chair and Department of Endocrinology, Diabetes, and Isotope Treatment, Wroclaw Medical University, Wroclaw, Poland
open access
Abstract
Cushing’s disease (CD) is a rare endocrine disorder characterized by the overproduction of adrenocorticotropic hormone (ACTH) by pituitary adenoma followed by hypercortisolaemia with severe complications. Although transsphenoidal resection of the defined pituitary adenoma has been the treatment of choice for the past decades, it does not always result in long-term remission — 10–30% of cases show ineffective surgical treatment or tumour recurrence even after initial success. Pharmacological therapies for cortisol reduction are often required for those who either cannot undergo pituitary surgery or when the surgery has failed, and patients still present with the persistent disease. Osilodrostat is a potent oral steroidogenesis inhibitor that has lately been shown as an effective adjuvant therapy in the management of patients with CD. In this article, we review the recent reports on the efficacy and safety of osilodrostat in clinical settings.
Abstract
Cushing’s disease (CD) is a rare endocrine disorder characterized by the overproduction of adrenocorticotropic hormone (ACTH) by pituitary adenoma followed by hypercortisolaemia with severe complications. Although transsphenoidal resection of the defined pituitary adenoma has been the treatment of choice for the past decades, it does not always result in long-term remission — 10–30% of cases show ineffective surgical treatment or tumour recurrence even after initial success. Pharmacological therapies for cortisol reduction are often required for those who either cannot undergo pituitary surgery or when the surgery has failed, and patients still present with the persistent disease. Osilodrostat is a potent oral steroidogenesis inhibitor that has lately been shown as an effective adjuvant therapy in the management of patients with CD. In this article, we review the recent reports on the efficacy and safety of osilodrostat in clinical settings.
Keywords
Cushing’s disease; hypercortisolism; osilodrostat; steroidogenesis inhibitors; cortisol
About this articleTitle
Osilodrostat — an emerging drug for the medical management of Cushing’s disease
Journal
Issue
Article type
Review paper
Pages
371-374
Published online
2022-04-05
Page views
5788
Article views/downloads
1026
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2022;73(2):371-374.
Keywords
Cushing’s disease
hypercortisolism
osilodrostat
steroidogenesis inhibitors
cortisol
Authors
Przemysław Witek
Anna Mehlich
Aleksandra Stasiewicz
Aleksandra Jawiarczyk-Przybyłowska
Marek Bolanowski
References (34)- Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015; 7: 281–293.
- Lonser RR, Nieman L, Oldfield EH. Cushing's disease: pathobiology, diagnosis, and management. J Neurosurg. 2017; 126(2): 404–417.
- Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab. 2013; 98(6): 2277–2284.
- Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013; 169(5): 715–723.
- Witek P, Zieliński G, Szamotulska K, et al. Complications of Cushing's disease - prospective evaluation and clinical characteristics. Do they affect the efficacy of surgical treatment? Endokrynol Pol. 2012; 63(4): 277–285.
- Witek P, Zieliński G, Szamotulska K, et al. Cushing`s disease: Fibrinogen and D-dimer levels fail to normalize despite early postoperative remission - a prospective, controlled study. Endokrynol Pol. 2016; 67(3): 283–291.
- Pivonello R, De Leo M, Cozzolino A, et al. The Treatment of Cushing's Disease. Endocr Rev. 2015; 36(4): 385–486.
- Nieman LK, Biller BMK, Findling JW, et al. Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(8): 2807–2831.
- Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab. 1995; 80(11): 3114–3120.
- Hofmann BM, Hlavac M, Martinez R, et al. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg. 2008; 108(1): 9–18.
- Lambert JK, Goldberg L, Fayngold S, et al. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. J Clin Endocrinol Metab. 2013; 98(3): 1022–1030.
- Witek P, Zieliński G, Maksymowicz M, et al. Cushing's disease -- assessing the efficacy of transsphenoidal surgery. Endokrynol Pol. 2012; 63(5): 398–404.
- Juszczak A, Grossman A. The management of Cushing's disease - from investigation to treatment. Endokrynol Pol. 2013; 64(2): 166–174.
- Pivonello R, Ferrigno R, De Martino MC, et al. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. Front Endocrinol (Lausanne). 2020; 11: 648.
- Colao A, Petersenn S, Newell-Price J, et al. Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012; 366(10): 914–924.
- Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018; 6(1): 17–26.
- Grossman A. Is the new treatment for Cushing's disease too sweet? Lancet Diabetes Endocrinol. 2018; 6(1): 2–3.
- Samson SL, Gu F, Feldt-Rasmussen U, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary. 2021; 24(6): 887–903.
- Mccance DR, Ritchie CM, Sheridan B, et al. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet. 1987; 329(8532): 573.
- Igaz P, Tömböl Z, Szabó PM, et al. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem. 2008; 15(26): 2734–2747.
- Fleseriu M, Pivonello R, Elenkova A, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019; 7(11): 855–865.
- Pivonello R, Elenkova A, Fleseriu M, et al. Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Front Endocrinol (Lausanne). 2021; 12: 595894.
- Fleseriu M, Auchus RJ, Pivonello R, et al. Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. Expert Rev Endocrinol Metab. 2021; 16(4): 159–174.
- Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020; 8(9): 748–761.
- Creemers SG, Feelders RA, de Jong FH, et al. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study. J Clin Endocrinol Metab. 2019; 104(8): 3437–3449.
- Menard J, Watson C, Rebello S, et al. Hormonal and electrolyte responses to the aldosterone synthase inhibitor lci699 in sodium depleted healthy subjects. . J Am College Cardiol. 2010; 55(10): A61.E583.
- Ménard J, Rigel DF, Watson C, et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med. 2014; 12: 340.
- Wang HZ, Tian JB, Yang KH. Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review. Eur Rev Med Pharmacol Sci. 2015; 19(2): 296–304.
- Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014; 99(4): 1375–1383.
- Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary. 2016; 19(2): 138–148.
- Webb SM, Badia X, Barahona MJ, et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol. 2008; 158(5): 623–630.
- Dougherty JA, Desai DS, Herrera JB. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease. Ann Pharmacother. 2021; 55(8): 1050–1060.
- Gadelha M, Bex M, Feelders R, et al. Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4). J Endocrin Soc. 2021; 5(Supplement_1): A516–A517.
- Simões Corrêa Galendi J, Correa Neto AN, Demetres M, et al. Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021; 12: 732240.
